Absorption and Presystemic Metabolism
The pharmacokinetic profile of metoprolol is rooted in its chemical nature as a pronounced lipophilic compound. Due to high lipid solubility, the drug demonstrates excellent gastrointestinal absorption: more than 90% of the active substance is absorbed from the intestine after oral administration.
However, high absorption does not correlate with the final blood concentration. The systemic bioavailability of metoprolol remains paradoxically low at only 40 to 50 percent. This pharmacokinetic phenomenon is caused by intensive presystemic metabolism in hepatocytes, also known in clinical pharmacology as the "first-pass effect" through the liver. Upon entering the portal venous system, a significant portion of the molecules undergoes immediate enzymatic transformation without ever reaching the systemic circulation.
Genetic Polymorphism and CYP2D6
The key enzyme responsible for the biotransformation of metoprolol in the body is the cytochrome CYP2D6 isoenzyme. A major clinical challenge is the pronounced genetic polymorphism of this enzyme within the human population, making the rate of drug cleavage and elimination a strictly individual parameter.
Depending on the genetic profile, the half-life ($T_{1/2}$) can vary widely—from a standard 3 hours to a prolonged 7–8 hours. Special attention is required when treating so-called "poor metabolizers." Such patients have a genetically determined abnormally low activity of hepatic enzyme systems. Consequently, plasma drug concentrations rise rapidly, and the risk of severe adverse effects increases approximately 5-fold compared to individuals with a normal metabolic phenotype.
Mechanism of Action: Pharmacodynamic Nuances
Regarding its cellular mechanism of action, metoprolol has a crucial feature that distinguishes it from simple blockers: the drug acts as an inverse agonist.
This means the molecule does more than competitively shield the receptor from endogenous catecholamines (epinephrine and norepinephrine). Metoprolol actively suppresses the spontaneous, or basal, activity of $\beta$-adrenoceptors. Even in the complete absence of a stimulating ligand, receptors can maintain a baseline level of activation, and metoprolol's unique ability to abolish this basal level ensures its consistently high therapeutic efficacy.
Clinical Application
Indications for this agent are generally similar to those for propranolol. Two main routes of administration are used in medical practice:
- Intravenously — for the rapid management of acute conditions.
- Orally — for long-term maintenance therapy. It is recommended to take the drug with meals, typically 2–3 times a day.
A specific approach is required when treating patients with chronic heart failure (CHF). In such clinical scenarios, standard immediate-release formulations are irrational and can be hazardous. Therefore, CHF management relies exclusively on specialized extended-release preparations (e.g., Betaloc ZOK or Egilok retard). These maintain a stable therapeutic concentration of the active substance by smoothing out peaks and troughs, which is vital for a failing myocardium.